Everest Organics Seeks Shareholder Approval for Board Restructuring Through Postal Ballot

Everest Organics Limited , a pharmaceutical company, has issued a postal ballot notice to seek shareholder approval for three special resolutions aimed at restructuring its board of directors. The company is proposing significant changes in its leadership structure, including new appointments and changes in designations.

Key Proposals

Appointment of New Whole-Time Director: The company proposes to appoint Mr. Venkata Satya Subbarao Pachigolla as a Whole-Time Director, designated as Executive Director. If approved, Mr. Pachigolla will serve for a term of three years, from November 12, 2025, to November 11, 2028, with a monthly remuneration of Rs. 2,00,000.
Change in Designation - Non-Executive to Independent Director: The board seeks to redesignate Mr. Kirankumar Rampally from Non-Executive Non-Independent Director to Non-Executive Independent Director, effective November 12, 2025.
Change in Designation - Independent to Non-Independent Director: The company proposes to change the designation of Mr. Prasad Venkata Satya Sundara Srikakolapu from Non-Executive Independent Director to Non-Executive Non-Independent Director, also effective from November 12, 2025.

Voting Process

Everest Organics has set up a remote e-voting process for shareholders to cast their votes on these resolutions. The voting period is scheduled as follows:

Event	Date and Time
Start Date	November 17, 2025, at 9:00 AM (IST)
End Date	December 16, 2025, at 5:00 PM (IST)
Results Declaration	On or before December 18, 2025

Director Profiles

Mr. Venkata Satya Subbarao Pachigolla

Age: 52 years
Qualification: Master of Computer Applications from Osmania University
Experience: Over 25 years in information technology, analytics, and business solutions
Current Role: Founder & CEO of WebRocket Pvt. Ltd.

Mr. Kirankumar Rampally

Age: 63 years
Qualification: M. Tech (Chemical Engineering)
Experience: 36 years in various organizations, including roles as COO and President in pharmaceutical and biotechnology companies

Mr. Prasad Venkata Satya Sundara Srikakolapu

Age: 63 years
Qualification: M. Com., DBM & CAIIB
Experience: Around 30 years in the Banking Sector, retired as Chief General Manager from Union Bank of India

These proposed changes reflect Everest Organics' efforts to strengthen its board with diverse expertise in technology, pharmaceuticals, and finance. Shareholders are encouraged to review the detailed postal ballot notice and cast their votes before the deadline.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.60%	+2.15%	+8.35%	-0.10%	+188.20%	+66.13%

Everest Organics has reported a significant turnaround in its financial performance for the quarter ended September 30, 2025, alongside announcing key changes to its board composition. The company, which operates in the Active Pharmaceutical Ingredients (API) and intermediates segment, has shown resilience in the face of operational challenges.

Financial Performance

For the quarter ended September 30, 2025, Everest Organics reported:

Particulars	Q2 FY2026	Q2 FY2025	YoY Change
Revenue from Operations	10,022.53	7,210.48	+38.99%
Net Profit	59.47	-634.96	Turned Profitable

The company's performance for the half-year period ending September 30, 2025, also showed improvement:

Particulars	H1 FY2026	H1 FY2025	YoY Change
Net Profit	256.10	-929.03	Turned Profitable

Board Restructuring

The Board of Directors has approved several changes in its composition:

Appointment of Venkata Satya Subbarao Pachigolla as Additional Director (Whole-time Director), subject to shareholder approval via postal ballot.
Change in designation of Kirankumar Rampally from Non-Executive Non-Independent to Independent Director.
Change in designation of Prasad Venkata Satya Sundara Srikakolapu from Independent Director to Non-Executive Non-Independent.

These changes are aimed at strengthening the company's leadership and governance structure.

Operational Challenges

While the financial results show improvement, the company faces some operational challenges:

The company is operating at enhanced production levels without necessary approvals from the Telangana State Pollution Control Board (TSPCB). This could potentially impact the company's going concern status.
The auditor's report highlighted that the company has not provided for Rs 143 lakhs in interest claimed by suppliers for delayed payments.

Management's Response

The management has stated that they are addressing the issue with TSPCB and have applied for Consent for Establishment for the enhancement in capacities. The application is pending approval, although the company has obtained an Environmental Clearance Certificate for additional capacities.

Regarding the supplier payments, the management is negotiating with suppliers and expects that the liability for the claimed interest will not subsist.

Conclusion

Despite the operational challenges, Everest Organics has shown a marked improvement in its financial performance. The board restructuring may bring fresh perspectives to address these challenges. However, investors should closely monitor the resolution of regulatory compliance issues and supplier negotiations in the coming quarters.

The company's ability to maintain its improved financial performance while resolving these operational issues will be crucial for its long-term sustainability and growth in the competitive API market.